(NYSEMKT: LCTX) Lineage Cell Therapeutics's forecast annual revenue growth rate of 54.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.29%.
Lineage Cell Therapeutics's revenue in 2026 is $14,556,000.On average, 9 Wall Street analysts forecast LCTX's revenue for 2026 to be $5,647,063,370, with the lowest LCTX revenue forecast at $817,754,358, and the highest LCTX revenue forecast at $8,966,652,869. On average, 8 Wall Street analysts forecast LCTX's revenue for 2027 to be $5,814,201,102, with the lowest LCTX revenue forecast at $817,754,358, and the highest LCTX revenue forecast at $19,589,488,718.
In 2028, LCTX is forecast to generate $14,748,970,767 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $48,004,148,589.